PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
3.220
+0.010 (0.31%)
At close: Aug 8, 2025, 4:00 PM
3.280
+0.060 (1.86%)
After-hours: Aug 8, 2025, 4:51 PM EDT
ShockWave Medical Employees
As of December 31, 2024, PolyPid had 60 total employees, including 57 full-time and 3 part-time employees. The number of employees decreased by 2 or -3.23% compared to the previous year.
Employees
60
Change (1Y)
-2
Growth (1Y)
-3.23%
Revenue / Employee
n/a
Profits / Employee
-$514,033
Market Cap
32.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 60 | -2 | -3.23% |
| Dec 31, 2023 | 62 | 2 | 3.33% |
| Dec 31, 2022 | 60 | -19 | -24.05% |
| Dec 31, 2021 | 79 | 10 | 14.49% |
| Dec 31, 2020 | 69 | 11 | 18.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PYPD News
- 10 days ago - PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025 - GlobeNewsWire
- 25 days ago - PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market - GlobeNewsWire
- 7 weeks ago - PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewsWire
- 2 months ago - PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention - GlobeNewsWire
- 2 months ago - PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention - GlobeNewsWire
- 2 months ago - BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript - GlobeNewsWire
- 2 months ago - PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints - GlobeNewsWire
- 2 months ago - PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 - GlobeNewsWire